Neos Therapeutics, Inc   Report issue

For profit Phase 3
Founded: Grand Prairie TX United States (2008)
Status: Acquired by AYTU BioScience (1966)

Organization Overview

First Clinical Trial
2013
NCT01835548
First Marketed Drug
2012
hydrocodone (hycodan)
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NEOS THERAP INC | NEOS THERAPS | NEOS THERAPS INC

Active Ingredients

Marketed Drugs (4)

Key: Neos Therapeutics, Inc (3) Acquired (1)

amphetamine (Adderall) (2016)

chlorpheniramine (ChlorTrimeton) (2012)

hydrocodone (hycodan) (2012)

methylphenidate (ritalin) (2017)

Drugs in Phase 3 Trials (2)

Key: Neos Therapeutics, Inc (0) Acquired (2)

enzastaurin (1 trial)

methylphenidate (ritalin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Hyperkinesis (Phase 3)

Overview

  • Highest Phase: None
  • # of Trials: 2
  • # of Trial APIs: 2